MedTrace Logo

Effects of a Novel Supplement on Glycemic Variability Measured by Continuous Glucose Monitoring

NCT05832463 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2023-04-27

No results posted yet for this study

Summary

This is a two-cohort, crossover pilot study to determine interstitial glucose levels coincident with the consumption of a novel carbohydrate blocking supplement.

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

Carbohydrate blocking supplement (CBS)

The CBS is composed of a Hypromellose outer shell, and filled with mulberry leaf extract, berberine HCl, cinnamon bark powder, and cinnamon bark essential oil. Mulberry leaf extract (Reducose) - 250 mg Berberine HCl (97%)(Berberis aristata root extract)- 25 mg Organic cinnamon powder (Cinnamon (Cinnamomum loureirii) bark powder) - 20 mg Essential oil blend (Grapefruit (Citrus paradisii) peel oil, Lemon (Citrus limon) peel oil Peppermint (Mentha piperita) aerial (leaf/stem) oil), Ginger (Zingiber officinale) root oil, Cinnamon (Cinnamomum zeylanicum) bark oil) - 5 mg

DIETARY_SUPPLEMENT

Placebo capsule

The placebo is composed of a Hypromellose outer shell filled with extra virgin olive oil.

Sponsors & Collaborators

  • dōTERRA International

    lead INDUSTRY

Principal Investigators

  • Russell Osguthorpe, MD · doTERRA International

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-14
Primary Completion
2022-07-12
Completion
2022-07-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05832463 on ClinicalTrials.gov